- Home
- GBLI vs AQST Comparison
GBLI vs AQST Comparison
Compare GBLI & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GBLI
- AQST
- Stock Information
- Founded
- GBLI 2016
- AQST 2004
- Country
- GBLI United States
- AQST United States
- Employees
- GBLI N/A
- AQST N/A
- Industry
- GBLI Property-Casualty Insurers
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- GBLI Finance
- AQST Health Care
- Exchange
- GBLI Nasdaq
- AQST Nasdaq
- Market Cap
- GBLI 421.5M
- AQST 390.4M
- IPO Year
- GBLI 2003
- AQST 2018
- Fundamental
- Price
- GBLI $29.25
- AQST $5.09
- Analyst Decision
- GBLI
- AQST Strong Buy
- Analyst Count
- GBLI 0
- AQST 7
- Target Price
- GBLI N/A
- AQST $10.29
- AVG Volume (30 Days)
- GBLI 2.9K
- AQST 2.6M
- Earning Date
- GBLI 11-06-2025
- AQST 11-03-2025
- Dividend Yield
- GBLI 4.79%
- AQST N/A
- EPS Growth
- GBLI N/A
- AQST N/A
- EPS
- GBLI 1.98
- AQST N/A
- Revenue
- GBLI $439,280,000.00
- AQST $44,132,000.00
- Revenue This Year
- GBLI $5.48
- AQST N/A
- Revenue Next Year
- GBLI $7.91
- AQST $38.71
- P/E Ratio
- GBLI $14.75
- AQST N/A
- Revenue Growth
- GBLI N/A
- AQST N/A
- 52 Week Low
- GBLI $26.94
- AQST $2.12
- 52 Week High
- GBLI $37.00
- AQST $5.80
- Technical
- Relative Strength Index (RSI)
- GBLI 45.75
- AQST 67.16
- Support Level
- GBLI $29.15
- AQST $4.75
- Resistance Level
- GBLI $29.63
- AQST $5.60
- Average True Range (ATR)
- GBLI 0.39
- AQST 0.29
- MACD
- GBLI 0.00
- AQST 0.10
- Stochastic Oscillator
- GBLI 13.61
- AQST 72.46
About GBLI Global Indemnity Group LLC (DE)
Global Indemnity Group LLC provides both admitted and non-admitted specialty property and casualty insurance coverages and individual policyholder coverages in the United States, as well as reinsurance world-wide. The company's two segments are: Penn-America and Non-Core Operations. The Penn-America segment offers specialty property and casualty products designed for its Wholesale Commercial, Specialty Products, InsurTech, and Assumed Reinsurance product offerings. These product lines are offered in the excess and surplus lines marketplace; and Non-Core Operations segment contains lines of business that have been de-emphasized or are no longer being written. The majority of its revenue is from the the Penn-America segment . Geographically, the majority is from California.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.